Eisai为阿尔茨海默氏病的Tau 抗体E2814提供了大有希望的第二阶段试验结果。 Eisai presents promising Phase II trial results for tau antibody E2814 in Alzheimer's disease.

日本制药公司Eisai在CTAD会议上介绍了其调查性Tau抗体E2814的调查结果。 Eisai, a Japanese pharmaceutical company, presented findings on its investigational tau antibody, E2814, at the CTAD conference. 该研究显示,患有遗传性老年痴呆症的病人的Tau蛋白质水平显著下降,这表明E2814可能会抑制Tau的传播和积累。 The study showed significant reductions in tau protein levels in patients with Dominantly Inherited Alzheimer's Disease, suggesting E2814 may inhibit tau propagation and accumulation. Eisai为早期阿尔茨海默氏病患者启动了第二阶段临床试验,以评估E2814与Lecanemab一起的安全性和功效,目的是改善患者的结果。 Eisai has launched a Phase II clinical trial for early Alzheimer's patients to assess the safety and efficacy of E2814 alongside lecanemab, aiming to improve patient outcomes.